Marker Therapeutics, Inc. (MRKR)
1.66
-0.34
(-17.00%)
USD |
NASDAQ |
Jan 12, 09:46
Marker Therapeutics Research and Development Expense (Quarterly): 2.346M for Sept. 30, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| ADMA Biologics, Inc. | 1.528M |
| Viridian Therapeutics, Inc. | 86.15M |
| Neurocrine Biosciences, Inc. | 250.00M |
| Kiniksa Pharmaceuticals International Plc | 24.14M |
| AIM ImmunoTech, Inc. | 0.525M |